Back to Legislators
Mr. Armstrong

Mr. Armstrong

Policy Effects

Estimated effects on people, organizations, and industries in bills this legislator sponsored, cosponsored, or voted on. Includes bills they voted against.

These are assessments of legislative text, not measurements of realized outcomes or the legislator’s intent.

Food and Drug Administration: supporting evidence

5 identified effects across 5 analyzed clauses in 1 bill.

Numbers count identified effects. One clause can affect several groups or contain several effects.

S3788-119

Reported

CLEAR LABELS Act

Mr. Armstrong’s recorded connection

Cosponsored this bill

  • Potential benefit to Food and Drug Administration

    Fewer compliance requirements

Summary unavailable

6. Effective date The amendments made by this Act shall apply to active pharmaceutical ingredients and finished drug products that are manufactured and packaged on or after the date that is 5 years after the date of enactment of this Act.
  • Potential burden on Food and Drug Administration

    More compliance requirements

Summary unavailable

4. Agency coordination regarding FDA and customs country of origin requirements In carrying out the amendments made by this Act, the Commissioner of Food and Drugs shall coordinate with the Commissioner of U.S. Customs and Border Protection on efforts to address the potential administrative burden on manufacturers of active pharmaceutical ingredients and finished drug products related to any pote…
  • Unclear effects on Food and Drug Administration

    No material effect identified

Summary unavailable

2. Require drug labeling to include original manufacturer and supply chain information Section 502(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352(b)) is amended— by striking containing (1) the name and place of business of the manufacturer, packer, or distributor and inserting the following: “containing— (A)the name, place of business, and unique facility identifier of the manufact…
  • Potential burden on Food and Drug Administration

    More compliance requirements

Summary unavailable

2. Require drug labels to include original manufacturer and supply chain information Section 503 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353) is amended by adding at the end the following — (i)Original Manufacturer and Supply Chain Information(1)In generalNo person shall introduce or deliver for introduction into interstate commerce any drug—(A)if it is an active pharmaceutical ing…
  • Potential burden on Food and Drug Administration

    More compliance requirements

Adds or tightens a compliance mandate, definition change, delegation of rulemaking provision: 2. Require drug labeling to include original manufacturer and supply chain information Section 502(b) of the Federal Food,... In practical terms, health care providers and patients face compliance burden up (negative); Federal implementing agencies face compliance burden up (negative).

Clause analysis

What the effects and counts mean

Potential benefits are effects assessed as favorable to the named group. Potential burdens impose costs, restrictions, risks, or lost opportunities on that group.

Mixed effects contain countervailing effects on the same group. Unclear effects have an undetermined direction. A group can have separate benefits and burdens; these are counted separately.

Counts describe the number of identified effects, not their size or public value. Bill and clause counts are distinct within each view. Shared evidence may appear under several groups or policy areas, so their counts should not be added together.

Historical bill versions are included. Clauses analyzed in different versions count separately. A bill’s current status does not establish that every analyzed provision was enacted.

Only direct effects with high or medium confidence in the policy-area assignment are included. Bills are connected through sponsorship, cosponsorship, or Yea/Nay votes; a vote against a bill does not reverse its assessed effects. Vote dates filter recorded votes and vote-linked bills; sponsorship remains included.

Loading countries...

Explore affected groups in Policy Effects to view supporting evidence. Existing clause links also open here.